SCHEDULE: Biogen Divests Entire Stake in Sage Therapeutics

Biogen Inc. and Biogen MA Inc. have fully divested their 9.941% beneficial ownership in Sage Therapeutics, Inc. by selling all 6,241,473 shares at $8.53 per share.

Summary

• Biogen Inc. and Biogen MA Inc. (the "Reporting Persons") previously held 6,241,473 shares of Sage Therapeutics, Inc. Common Stock as of July 28, 2025.
• This stake represented 9.941% of Sage Therapeutics' 62,784,397 issued and outstanding shares as of July 23, 2025.
• On July 29, 2025, the Reporting Persons sold all of their shares in a block trade at a price of $8.53 per share.
• As of the filing date, Biogen Inc. and Biogen MA Inc. beneficially own 0.00% of Sage Therapeutics' Common Stock, holding no shares.
• The Reporting Persons ceased to be beneficial owners of more than five percent of Sage Therapeutics' Common Stock on July 29, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative for Sage Therapeutics due to the complete divestment by a major institutional shareholder, which can signal a lack of confidence or strategic misalignment. For Biogen, it's a neutral to slightly positive event as it represents a portfolio adjustment and capital realization.

Positives

• For Biogen, the divestment frees up capital and streamlines its investment portfolio.

Negatives

• For Sage Therapeutics, the complete divestment by a significant institutional investor like Biogen could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in strategic alignment.
• The sale of 6,241,473 shares in a block trade could exert downward pressure on Sage Therapeutics' stock price.

Risks

• The exit of a major institutional shareholder like Biogen could lead to decreased investor confidence in Sage Therapeutics.
• Increased selling pressure on Sage Therapeutics' stock due to the large block trade could negatively impact its share price.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the future operations or financial performance of Sage Therapeutics or Biogen Inc. beyond the completion of the share sale.

Industry Context

This divestment by Biogen, a major pharmaceutical company, from Sage Therapeutics, a biopharmaceutical company, highlights a shift in investment strategy or portfolio optimization within the biotech and pharma sectors. Such large-scale exits by institutional investors can influence market perception and potentially impact the valuation of smaller biotech firms, especially if the exiting investor was previously involved in strategic partnerships or collaborations.

Stakeholder Impact

• Shareholders of Sage Therapeutics may experience a negative impact on share price due to the large block sale and potential loss of investor confidence.
• The divestment could lead to questions among investors regarding the long-term strategic direction or financial health of Sage Therapeutics, especially if Biogen was seen as a strategic partner.

Key Dates

Recommendation

The complete divestment by a major institutional investor like Biogen, representing nearly 10% of outstanding shares, is a strong negative signal for Sage Therapeutics. Such a large-scale exit often indicates a lack of confidence or a strategic shift away from the company, which can lead to significant downward pressure on the stock price. Seasoned investors would likely view this as a reason to sell or reduce their holdings in Sage Therapeutics, anticipating potential further declines or a prolonged period of underperformance.

Keywords

Sage Therapeutics, Biogen, SEC filing, Schedule 13D, stock sale, divestment, institutional ownership, biotechnology, pharmaceuticals, shareholder, block trade